Group A streptococcal SpeB modifies IgA through targeting regions other than the hinge

Area of Science:

• Microbiology
• Immunology
• Molecular Biology

Background:

• Bacterial immune evasion often involves immunoglobulin (Ig) degradation.
• Mucosal colonization by pathogens like Group A Streptococcus (GAS) relies on overcoming host defenses, including IgA.
• GAS lacks a known specialized IgA protease targeting the IgA1 hinge region, despite its mucosal presence.

Purpose of the Study:

• To investigate the interaction between the GAS cysteine protease SpeB and human immunoglobulin A (IgA).
• To determine if SpeB modifies IgA and to characterize the nature of this modification.
• To explore the potential role of SpeB-mediated IgA modification in GAS immune evasion during mucosal colonization.

Main Methods:

• Analysis of bacterial supernatants from wild-type and speB-deficient GAS strains.
• Use of recombinant SpeB to assess IgA-modifying activity.
• Mass spectrometry and glycosylation profiling to identify modification sites and products.

Main Results:

• SpeB demonstrated a clear, dose-dependent IgA-modifying activity.
• SpeB degraded multimeric forms of IgA, with a pronounced effect on IgA2, leading to smaller products lacking the heavy chain.
• Mass spectrometry and glycosylation data suggested cleavage in the C-terminal tailpiece, not the hinge region, causing loss of dimeric/multimeric IgA.

Conclusions:

• GAS cysteine protease SpeB modifies human IgA, primarily affecting multimeric forms of IgA2.
• The modification occurs at the C-terminus, distinct from typical IgA protease cleavage sites.
• SpeB-mediated IgA modification represents a potential novel immune evasion mechanism for GAS at mucosal surfaces.